MARSHALL KEITH W (Chief Financial Officer) sold 50.5% of their position (10K shares) of PROMETHEUS BIOSCIENCES, INC. on the open market
Open‑market sale worth $1.08M — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 4/7/2023ACC: 0001209191-23-023869
Officer· Chief Financial Officer
Since Mar 2021
-10K
Net shares
Net seller
$1.08M
Total sold
1
Open market trades
0B · 1S
3
Total transactions
10K acquired · 20K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+10K
Price / share
$3.70
Trade value
$37K
% of position
101.9%
4/5/2023
9.81K→19.81K
Common Stock
Direct
Shares
−10K
Price / share
$108.42
Trade value
$1.08M
% of position
50.5%
4/5/2023
19.81K→9.81K
Total
Net shares
+0.00
Net value
-$1.05M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/5/2023 | M · Option Exercise | +10K | $3.70 | $37K | 101.9% | 9.81K | 19.81K |
| Common Stock Direct | 4/5/2023 | S · Sale | −10K | $108.42 | $1.08M | 50.5% | 19.81K | 9.81K |
| Total | +0.00 | -$1.05M | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
10K shares
Shares
−10K
Strike price
3.70
Held after
93.04K
Exercisable
—
4/5/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock10K shares | 4/5/2023 | M · Option Exercise | −10K | 3.70 | — | 93.04K |